SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) and Lead Plaintiff Deadline: January 17, 2017

News provided by

Nov 18, 2016, 10:20 ET

NEW YORK, Nov. 18, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") (NASDAQ: ALXN) and certain of its officers, and is on behalf of shareholders who purchased or otherwise acquired Alexion securities between February 10, 2014 and November 9, 2016, both dates inclusive (the "Class Period"). Such investors are advised to join this case by visiting the firm's site: http://www.bgandg.com/alxn.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act").

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose: (1) that Alexion engaged in inappropriate sales practices in connection with Soliris; (2) that Alexion's revenues from Soliris sales were not likely to be maintained; and (3) consequently, Alexion's public statements were materially false and misleading at all relevant times.

On November 4, 2016, Alexion cancelled its attendance at the Credit Suisse Healthcare Conference, and shortly after analysts noticed that Alexion did not file its Quarterly Report on Form 10-Q with the SEC within two days of its earnings announcement on October 27, 2016.

On November 9, 2016, Alexion revealed that its top drug, Soliris, is being investigated for improper sales practices. Soliris is also estimated to account for 92% of Alexion's 2016 sales. Alexion also retained independent counsel and said it would be delaying its third-quarter financial report.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/alxn or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Alexion you have until January 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

Logo - http://photos.prnewswire.com/prnh/20161114/439152LOGO

SOURCE Bronstein, Gewirtz & Grossman, LLC